Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10968424 | Vaccine | 2012 | 8 Pages |
Abstract
⺠We modeled the impact of vaccination on risk of pneumococcal disease in older US adults. ⺠Model projections suggest that use of PCV13 (vs. PPSV23): (i) without revaccination, would reduce cases of disease and lower total costs; and (ii) with revaccination every 5-10 years, would result in the fewest cases and lowest costs. ⺠Projected impact of PCV13 in older US adults is favorable vs. current practice.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Derek Weycker, Reiko Sato, David Strutton, John Edelsberg, Mark Atwood, Lisa A. Jackson,